NCT04218552

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 176 (actual)
• Sponsor: Addpharma Inc. · Industry
• Sex: All
• Age: 19 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the optimal dose of AD-209 in patients with Essential Hypertension.

Detailed description

Condition or disease : hypertension Intervention/treatment Drug : AD-209-H Drug : AD-209-M Drug : AD-209-L Drug : Placebo Drug : Amlodipine Drug : Telmisartan Phase : Phase 2

Conditions

• Hypertension,Essential

Interventions

Type	Name	Description
DRUG	AD209	PO, Once daily(QD), 8weeks
DRUG	Amlodipine low	PO, Once daily(QD), 8weeks
DRUG	Amlodipine high	PO, Once daily(QD), 8weeks
DRUG	Telmisartan	PO, Once daily(QD), 8weeks

Timeline

• Start date: 2020-02-25
• Primary completion: 2021-02-25
• Completion: 2021-02-25
• First posted: 2020-01-06
• Last updated: 2021-07-21

Locations

1 site across 1 country: South Korea